期刊文献+

淋巴细胞参数在弥漫性大B细胞淋巴瘤诊断中的价值 被引量:4

Roles of lymphocyte parameters in the diagnosis of diffuse large B-cell lymphoma
下载PDF
导出
摘要 目的探讨淋巴细胞参数在弥漫性大B细胞淋巴瘤(DLBCL)诊断中的价值。方法选取体检健康者60名,作为对照组。另选取44例初诊DLBCL患者、24例慢性淋巴细胞白血病(CLL)患者、42例其他非霍奇金淋巴瘤(NHL)患者和40例传染性单核细胞增多症(IM)患者,比较DLBCL与其他各组淋巴细胞参数的差异。采用受试者工作特征(ROC)曲线探讨淋巴细胞参数对DLBCL的诊断效能。结果DLBCL组与对照组LY-X、LY-Y、LY-WZ差异有统计学意义,其诊断DLBCL的曲线下面积(AUC)分别为0.644、0.655、0.742,最佳临界值分别为76.9、69.1、536;DLBCL组与CLL组LY-X、LY-WX、LY-WY、LY-WZ差异有统计学意义,其诊断DLBCL的AUC分别为0.772、0.608、0.863、0.827,最佳临界值分别为79.4、612、1020、533;DLBCL组与其他NHL组LY-WZ差异有统计学意义,其诊断DLBCL的AUC为0.575,最佳临界值为588;DLBCL组与IM组LY-Z、LY-WX、LY-WY、LY-WZ差异有统计学意义,其诊断DLBCL的AUC分别为0.772、0.561、0.777、0.887,最佳临界值分别为60.9、612、1022、633。结论淋巴细胞参数对DLBCL有一定的诊断价值。 Objective To investigate the roles of lymphocyte parameters in the diagnosis of diffuse large B-cell lymphoma(DLBCL).Methods A total of 60 healthy subjects(healthy control group),44 patients with DLBCL,24 patients with chronic lymphocytic leukaemia(CLL),42 patients with other non-Hodgkin lymphomas(NHL)and 40 patients with infectious mononucleosis(IM)were enrolled,and their lymphocyte parameters were determined.The difference between DLBCL and the other groups was evaluated.Receiver operating characteristic(ROC)curve was used to evaluate the diagnostic efficiency of different lymphocyte parameters for DLBCL.Results Compared with healthy control group,DLBCL group had statistical significance in LY-X,LY-Y and LY-WZ,their areas under ROC curves(AUC)were 0.644,0.655 and 0.742,and the optimal cut-off values were 76.9,69.1 and 536,respectively.Compared with CLL group,the differences of LY-X,LY-WX,LY-WY and LY-WZ were statistically significant,the AUC were 0.772,0.608,0.863 and 0.827,and the optimal cut-off values were 79.4,612,1020 and 533,respectively.Compared with other NHL group,LY-WZ had statistical significance,the AUC was 0.575,and the optimal cut-off value was 588.Compared with IM group,LY-Z,LY-WX,LY-WY and LY-WZ were statistically significant,the AUC were 0.772,0.561,0.777 and 0.887,and the optimal cut-off values were 60.9,612,1022 and 633,respectively.Conclusions Lymphocyte parameters have a certain value for the diagnosis of DLBCL.
作者 袁钦伟 郭永灿 陈忱 叶润发 YUAN Qinwei;GUOYongcan;CHEN Chen;YE Runfa(Department of Clinical Laboratory,the Traditional Chinese Medicine Hospital of Southwest Medical University,Luzhou 646000,Sichuan,China)
出处 《检验医学》 CAS 2019年第12期1114-1117,共4页 Laboratory Medicine
关键词 弥漫性大B细胞淋巴瘤 淋巴细胞参数 诊断价值 Diffuse large B-cell lymphoma Lymphocyte parameter Diagnostic value
  • 相关文献

参考文献3

二级参考文献23

  • 1王晋芬,王云中,陈振文,Taylor Clive R.根据WHO淋巴造血系统肿瘤新分类对山西省淋巴瘤分布特点的分析[J].中华病理学杂志,2006,35(4):218-223. 被引量:24
  • 2Nedomova R, Papajik T, Prochazka V, et al. Cytogenetics and mo- lecular cytogenetics in diffuse large B-cell lymphoma (DLBCL)[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2013, 157(3) :239-247.
  • 3Raut LS, Chakrabarti PP. Management of relapsed-refractory dif- fuse large B cell lymphoma[J]. South Asian J Cancer, 2014, 3(1): 66-70.
  • 4Porrata LF, Ristow K, Habermann TM, et al. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma[J]. Am J Hematol, 2009, 84(2): 93-97.
  • 5Wilcox RA, Ristow K, Habermann TM, et al. The absolutemono- cyte and lymphocyte prognostic score predictssurvival and identi- fies high-risk patientsin diffuse large-B-cell lymphoma[J]. Leuke-mia, 2011, 25(9):1502--1509.
  • 6Aoki T, Nishiyama T, Imahashi N, et al. Lymphopenia following the completion of first--line therapy predicts early relapse in pa- tients with diffuse large B cell lymphoma[J]. Ann Hematol, 2012, 91 (3):375--382.
  • 7Li ZM, HuangJJ, Xia Yet al. Blood lymphocyte-to-monocyte ra- tio identifies high-risk patientsin diffuse large B-cell lymphoma treated with R-CHOP[J]. PIoS One, 2012, 7(7):e41658.
  • 8A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Proj- ecr[J]. NenglJ Med, 1993, 329(14):987-994.
  • 9Jabbour E, Peslin N, Arnaud P, et al. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive re- current or refractory non-Hodgkinls lymphomas treated with high--dose BEAM therapy and autologous stem cell transplantation [J]. Leuk Lymphoma, 2005, 46(6) :861-867.
  • 10Ray--Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival ha advanced carcinomas, sarcomas, and lymphomas[J]. Cancer Res, 2009, 69(13):5383-5391.

共引文献263

同被引文献38

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部